| 1 |
NCT01450657 |
Completed |
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients |
|
- Dietary Supplement: Kibow Biotics/Renadyl
|
Observational |
|
- Kibow Biotech Inc.
- Thomas Jefferson University
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 15-20% Changes in BUN.
- 15-20% Change in Creatinine
- Quality of life outcome based on questionnaire.
- (and 2 more...)
|
31 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01450657 |
KIB002 |
|
July 2011 |
September 2012 |
October 2012 |
October 12, 2011 |
August 18, 2017 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 2 |
NCT02586376 |
Completed |
Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF) |
|
- Device: 0J LLLT
- Device: 4J LLLT
- Device: 6J LLLT
- Device: 8J LLLT
|
Interventional |
Not Applicable |
- Federal University of Health Science of Porto Alegre
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Muscle Strength (Handgrip Test)
|
16 |
All |
30 Years to 60 Years (Adult) |
NCT02586376 |
LLLT-RENAIS-2015 |
LLLTMSKF |
October 2015 |
January 2016 |
February 2016 |
October 26, 2015 |
February 3, 2016 |
|
- Fabrício Edler Macagnan
Porto Alegre, RS, Brazil
|
| 3 |
NCT00760162 |
Completed |
Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- PRIMARY: Changes in blood chemistry - BUN, Creatinine and Uric acid
- Changes in BUN, Creatinine and uric acid levels
|
180 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00760162 |
KIB001 |
Probiotics |
August 2007 |
July 2009 |
August 2009 |
September 26, 2008 |
August 3, 2011 |
|
- Downstate Medical Center,HSCB, State University of New York
Brooklyn, New York, United States - SUNY DownState Medical Center-Renakl Division
Brooklyn, New York, United States
|
| 4 |
NCT02857556 |
Recruiting |
Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure |
- End-stage Chronic Kidney Failure
|
- Biological: Blood sample
- Other: Retinal photography:
- Other: dialyse
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire Dijon
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Activation of 5 proteins relocated in the membrane of monocytes (eNOS, iNOS, gp91phox and receptors of angiotensin II (AT1 and AT2)) within dynamic lipid structures, rafts, measured by western blot-dot blot.
|
160 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02857556 |
GAMBERT Fd. Transpl 2013 |
DIALYSOX |
April 2014 |
July 2018 |
|
August 5, 2016 |
August 5, 2016 |
|
- CHU Dijon Bourgogne
Dijon, France
|
| 5 |
NCT01231438 |
Completed |
Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder. |
|
- Drug: Renvela
- Drug: Etalpha
|
Interventional |
Phase 2 |
- Helse Stavanger HF
- Rikshospitalet University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- FGF23 serum level
- Calcium serum level
- Phosphate serum level
- (and 3 more...)
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT01231438 |
SUS2010GOLA01
2010-020415-36 |
|
October 2010 |
March 2011 |
March 2011 |
November 1, 2010 |
November 9, 2012 |
|
- Oslo Universitetssykehus Rikshospitalet
Oslo, Norway - Stavanger University Hospital
Stavanger, Norway
|
| 6 |
NCT01356966 |
Completed
Has Results |
Exercise Intolerance in Renal Failure |
|
- Drug: Tetrahydrobiopterin
- Drug: Placebo
- Dietary Supplement: Folate
|
Interventional |
Phase 2 |
- Emory University
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Resting Muscle Sympathetic Nerve Activity (MSNA)
- Change in Mean Central Augmentation Index (AIx)
- Change in Heart-rate-corrected Augmentation Index (AIx)
|
74 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01356966 |
IRB00019181
K23HL098744 |
EIRF |
May 2011 |
May 2014 |
May 2014 |
May 20, 2011 |
June 1, 2015 |
June 1, 2015 |
- Emory University Hospital
Atlanta, Georgia, United States - Atlanta VA Medical Center
Decatur, Georgia, United States
|
| 7 |
NCT00211653 |
Completed |
Acetylcysteine in the Prevention of Renal Failure After Bypass Surgery |
|
|
Interventional |
Phase 1
Phase 2 |
- Minneapolis Veterans Affairs Medical Center
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Rise in creatinine above baseline
- Creatinine increase >25% or =/> 0.5 mg/dl above baseline
- Length of stay in the ICU and the hospital
- Operative mortality
|
102 |
All |
18 Years and older (Adult, Senior) |
NCT00211653 |
3212-B |
|
April 2003 |
|
November 2006 |
September 21, 2005 |
September 19, 2007 |
|
- Veterans Affairs Medical Center
Minneapolis, Minnesota, United States
|
| 8 |
NCT00148044 |
Completed |
Uremic Toxins of Patients With Acute Kidney Failure |
|
- Procedure: Blood sampling for determination of uremic toxins
|
Observational |
|
- University Hospital, Ghent
|
Other |
- Time Perspective: Prospective
|
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00148044 |
2003/298 |
|
October 2003 |
|
February 2004 |
September 7, 2005 |
December 28, 2007 |
|
- University Hospital Ghent
Ghent, Belgium
|
| 9 |
NCT01227122 |
Unknown † |
NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure |
- Preoperative KIDNEY FAILURE, CHRONIC
- Postoperative KIDNEY FAILURE, ACUTE
- Cardiac Surgical Procedures
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Neutrophil Gelatinase Associated Lipocalin (NGAL) level
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01227122 |
2010-A00111-38 |
NGAL-CKF |
August 2010 |
July 2013 |
September 2013 |
October 25, 2010 |
March 4, 2013 |
|
- Centre hospitalier Universitaire (CHU) Jean Minjoz
Besançon, Franche-Comté, France
|
| 10 |
NCT00124969 |
Completed |
Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure |
|
- Drug: Amlodipine
- Drug: Placebo
|
Interventional |
Phase 4 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary outcome will be the survival rate. The secondary outcome will be cardiovascular events.
|
356 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT00124969 |
ADAM
AML-D-01-001G |
|
January 2002 |
|
October 2006 |
July 29, 2005 |
May 9, 2008 |
|
- Charite Campus Benjamin Franklin
Berlin, Germany
|
| 11 |
NCT00247325 |
Completed |
RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography |
|
|
Interventional |
Phase 4 |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Prevention
|
- Incidence of contrast induced nephropathy, defined as either a relative increase in serum creatinine from baseline of >=25% or an absolute increase of >=0.5mg/dL(44.2µmol/L) during days 1 and 2
- proportion of patients exhibiting an increase in serum creatinine of >=0.5mg/dL(44.2µmol/L), the proportion with a >=1.0 mg/dL(88.4µmol/L) increase in serum creatinine, and the mean peak increase in serum creatinine
|
|
All |
19 Years and older (Adult, Senior) |
NCT00247325 |
144-가-24 |
|
January 2004 |
|
December 2004 |
November 1, 2005 |
November 30, 2006 |
|
- Seoul National University Hospital , Cardiovascular Center
Seoul, Korea, Republic of
|
| 12 |
NCT00213291 |
Completed |
Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure |
|
|
Interventional |
Phase 3 |
- The Hospital for Sick Children
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety of darbepoetin when administered at an increased dosing interval
- Safety and tolerability of darbepoetin
- Proportion of subjects who receive red blood cell transfusions
- (and 2 more...)
|
40 |
All |
up to 17 Years (Child) |
NCT00213291 |
1000004731 |
|
April 2005 |
September 2005 |
October 2005 |
September 21, 2005 |
August 26, 2013 |
|
- The Hospital for Sick Children
Toronto, Ontario, Canada
|
| 13 |
NCT00356954 |
Completed |
NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization |
|
- Drug: N-acetylcystein
- Drug: ascorbic acid
|
Interventional |
Phase 4 |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- The mean peak increase of serum creatinine concentration during day1 and day2.
- Incidence of contrast induced nephropathy, defined as either a relative increase in serum creatinine
- from baseline of >=25% or an absolute increase of >=0.5mg/dL(44.2µmol/L) during days 1 and 2.
- (and 2 more...)
|
250 |
All |
19 Years and older (Adult, Senior) |
NCT00356954 |
H-0509-517-158-2 |
|
February 2005 |
|
April 2006 |
July 27, 2006 |
November 27, 2006 |
|
- Seoul National University Hospital , Cardiovascular Center
Seoul, Korea, Republic of
|
| 14 |
NCT00259441 |
Completed |
PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography |
|
|
Interventional |
Phase 4 |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- The mean peak increase of serum creatinine concentration during day1 and day2.
- Incidence of contrast induced nephropathy, defined as either a relative increase in serum creatinine from baseline of >=25% or an absolute increase of >=0.5mg/dL(44.2µmol/L) during days 1 and 2.
- Proportion of patients exhibiting an increase in serum creatinine of >=0.5mg/dL(44.2µmol/L), the proportion with a >=1.0 mg/dL(88.4µmol/L) increase in serum creatinine, and the mean peak increase in serum creatinine.
|
320 |
All |
19 Years and older (Adult, Senior) |
NCT00259441 |
H-0509-517-158 |
|
February 2005 |
|
March 2006 |
November 29, 2005 |
July 12, 2007 |
|
- Seoul National University Hospital , Cardiovascular Center
Seoul, Korea, Republic of
|
| 15 |
NCT01481610 |
Terminated |
Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia |
- Kidney Failure, Chronic
- Arthralgia
|
- Drug: Lumiracoxib
- Drug: Diclofenac
|
Interventional |
Phase 2 |
- Hospital Central Sur de Pemex
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in GFR
- Use of rescue medication
- Subjective improvement in pain
|
28 |
All |
60 Years and older (Adult, Senior) |
NCT01481610 |
PEMEX-805415-00-2 |
|
January 2012 |
November 2012 |
November 2012 |
November 29, 2011 |
February 13, 2013 |
|
- Hospital Central Sur de Alta Especialidad PEMEX
Mexico City, DF, Mexico
|
| 16 |
NCT00018317 |
Completed |
Resistance Training and Diet in Patients With Chronic Renal Failure |
|
- Behavioral: low protein diet
- Behavioral: resistance training
- Behavioral: combination of diet control and exercise
|
Interventional |
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
All |
50 Years to 89 Years (Adult, Senior) |
NCT00018317 |
AGCG-005-99F |
|
October 2000 |
|
December 2005 |
July 5, 2001 |
January 21, 2009 |
|
- Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States
|
| 17 |
NCT00230412 |
Unknown † |
Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study) |
|
|
Observational |
|
- University of Munich Children's Clinic
- Ludwig-Maximilians - University of Munich
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
120 |
All |
up to 18 Years (Child, Adult) |
NCT00230412 |
HSP-233-05
Projektnummer 233-05 |
HSP |
October 2005 |
|
December 2010 |
September 30, 2005 |
February 2, 2010 |
|
- Klinikum Augsburg, II. Klinik für Kinder und Jugendliche
Augsburg, Bavaria, Germany - Kinderklinik Memmingen
Memmingen, Bavaria, Germany - Klinikum der Universität München, Kinderklinik und Poliklinik im Dr. von Haunerschen Kinderspital
Munich, Bavaria, Germany - (and 3 more...)
|
| 18 |
NCT00522756 |
Unknown † |
Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy |
|
- Drug: Sodium bicarbonate
- Drug: Sodium chloride
|
Interventional |
Phase 3 |
- McGill University Health Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Increase in serum creatinine of 44 micromol/L or by 25% within the first 3 days after surgery.
- Postoperative vasoactive medication, intra-aortic balloon pump, mechanical ventilation, reintubation, reoperation, myocardial infarction, stroke, infection, hypokalemia, dialysis, ICU and hospital length of stay and survival.
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT00522756 |
SDR-05-045 |
PARACHUTE |
May 2006 |
December 2012 |
March 2013 |
August 30, 2007 |
October 24, 2012 |
|
- McGill University Health Centre - Royal Victoria Hospital
Montreal, Quebec, Canada
|
| 19 |
NCT02849964 |
Completed |
Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions |
|
|
Observational |
|
- Centre Hospitalier Universitaire de Besancon
- Agence de La Biomédecine
- Central Hospital, Nancy, France
- (and 2 more...)
|
Other |
- Observational Model: Ecologic or Community
- Time Perspective: Retrospective
|
- Factors associated with renal replacement therapy
|
6835 |
All |
18 Years and older (Adult, Senior) |
NCT02849964 |
VIgIE |
VIgIE |
September 2015 |
June 2016 |
June 2016 |
July 29, 2016 |
July 29, 2016 |
|
- Centre d'Investigation Clinique, CHU de Besançon
Besançon, France - Hôpital William Morey, Néphrologie
Chalon sur Saône, France - CHU de Reims, Néphrologie
Reims, France - Centre d'Investigation Clinique CHU de Nancy
Vandoeuvre-les-Nancy, France
|
| 20 |
NCT01453816 |
Withdrawn |
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure |
|
- Procedure: Harvesting and Isolation of Stem cells
|
Interventional |
Not Applicable |
- Ageless Regenerative Institute
- Instituto de Medicina Regenerativa, S.A. de C.V.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Significant clinical improvement in serum creatinine and urine output (improvement in measured Glomerular Filtration Rate(GFR) by 50%)
- number of participants with adverse events
- Significant clinical improvement in serum creatinine and urine output (improvement in measured Glomerular Filtration Rate(GFR) by 50%) at 6 months
- Improvement in renal biopsy measured by the reduction of scarring etc as compared to baseline
|
0 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01453816 |
ADI-ME-RF-001 |
|
May 2011 |
December 2014 |
June 2015 |
October 18, 2011 |
July 21, 2017 |
|
- Hospital Angeles
Tijuana, Baja California, Mexico
|
| 21 |
NCT00029796 |
Completed |
Isoflavones and Acute-phase Response in Chronic Renal Failure |
|
|
Interventional |
Phase 2 |
- National Center for Complementary and Integrative Health (NCCIH)
|
NIH |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Treatment
|
|
52 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00029796 |
R21AT000205-01A1 |
|
|
September 2003 |
September 2003 |
January 24, 2002 |
March 22, 2013 |
|
- University of Kentucky Medical Center
Lexington, Kentucky, United States
|
| 22 |
NCT00280072 |
Terminated |
Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure |
|
- Device: Renal Assist Device
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To evaluate all cause mortality at Day 28
- To assess the effect of RAD treatment in measures of patient's safety and clinical outcome
|
|
All |
18 Years to 80 Years (Adult, Senior) |
NCT00280072 |
RAD-003 |
|
January 2006 |
August 2007 |
August 2007 |
January 20, 2006 |
December 3, 2012 |
|
- University of Alabama
Birmingham, Alabama, United States - Denver Nephrologists, PC
Denver, Colorado, United States - George Washington University Hospital
Washington, District of Columbia, United States - (and 13 more...)
|
| 23 |
NCT01724788 |
Completed |
Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis |
|
- Drug: FUROSEMIDE
- Drug: FUROSEMIDE (HOE058)
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Absolute bioavailability (F) of a single 500-mg oral tablet
- To determine the pharmacokinetic parameters of furosemide (po and iv) measured by Cmax (maximum (peak) plasma drug concentration) after single dose administration
- To determine the pharmacokinetic parameters of furosemide (po and iv) measured by Tmax (time to reach peak or maximum concentration) following drug administration
- (and 2 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT01724788 |
FUROSL06121
U1111-1127-0839 |
|
November 2012 |
January 2013 |
January 2013 |
November 12, 2012 |
February 12, 2013 |
|
- Investigational Site Number 124002
Montreal, Canada
|
| 24 |
NCT00391287 |
Completed |
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure |
- Pure Red-Cell Aplasia
- Chronic Kidney Failure
|
|
Observational |
|
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Janssen-Cilag International NV
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- estimate the incidence rate of EPO antibody-mediated Pure Red Cell Aplasia (PRCA)
- sensitivity analyses
|
15334 |
All |
18 Years and older (Adult, Senior) |
NCT00391287 |
CR011587
EPOANE4014
001992-001 |
PRIMS |
June 2006 |
December 2010 |
December 2010 |
October 23, 2006 |
October 3, 2014 |
|
- Adelaide, Australia
- Central Queensland M C, Australia
- Fremantle, Australia
- (and 388 more...)
|
| 25 |
NCT01660295 |
Completed |
Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects |
|
- Drug: Certoparin 3,000 IU Once Daily
- Drug: Certoparin 3,000 IU Twice a Day
- Drug: Certoparin 8,000 IU Once Daily
- Drug: Certoparin 8,000 IU Twice a Day
|
Interventional |
Phase 1
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma aXa-Profile: C0
- Dose regimen, systemic total exposure to aXa (AUC0-τ,ss)
- Plasma aXa-Profile: Cmax
- Plasma aXa-Profile: AUC
|
32 |
All |
21 Years to 60 Years (Adult) |
NCT01660295 |
CMEX839BDE07
2011-001930-40 |
|
December 2011 |
June 2012 |
|
August 8, 2012 |
August 8, 2012 |
|
- DRC Drug Research Center Ltd., H-8230 Balatonfüred
H-8230 Balatonfüred, Ady E. u., Hungary
|
| 26 |
NCT01135979 |
Withdrawn |
Assessment of the Sympathetic Nervous System Blockade of the Upper Limb After a Brachial Plexus Block in Patients With End Stage Renal Failure |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01135979 |
07AN007 |
|
February 2010 |
December 2012 |
December 2012 |
June 3, 2010 |
March 6, 2013 |
|
- Nottingham University Hospitals NHS Trust
Nottingham, Nottinghamshire, United Kingdom
|
| 27 |
NCT02815774 |
Completed |
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients |
|
|
Interventional |
Phase 1 |
- Jiangsu HengRui Medicine Co., Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The maximum plasma concentration (Cmax) of SP2086
- The maximum plasma concentration (Cmax) of SP2086 acid
- The area under the plasma concentration-time curve (AUC) of SP2086
- (and 2 more...)
|
30 |
All |
18 Years to 79 Years (Adult, Senior) |
NCT02815774 |
HR-SP2086-Ih |
|
June 2014 |
January 2015 |
January 2015 |
June 28, 2016 |
June 28, 2016 |
|
|
| 28 |
NCT00599391 |
Unknown † |
Far Infrared Treatment for Kidney Diseases |
|
- Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
|
Interventional |
Phase 1 |
- GAAD Medical Research Institute Inc.
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Kidney Function Improvement
- Causes of Mortality
|
10 |
All |
Child, Adult, Senior |
NCT00599391 |
GAAD-RF-CTP1 |
|
February 2008 |
October 2008 |
February 2009 |
January 23, 2008 |
January 5, 2009 |
|
- The Centre for Incurable Diseases
Toronto, Ontario, Canada
|
| 29 |
NCT02468440 |
Active, not recruiting |
Evaluation of ESPAIR, an Educational Therapy's Program of Patients With Renal Insufficiency Before Kidney Transplant |
|
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Quality of life Questionnaire
- Composite measure of impact of educational therapy's program
|
224 |
All |
18 Years and older (Adult, Senior) |
NCT02468440 |
14 7314 02
2015/20 |
ESPAIR |
June 2015 |
December 2018 |
December 2018 |
June 10, 2015 |
March 27, 2018 |
|
- Chu Toulouse
Toulouse, France
|
| 30 |
NCT01468051 |
Completed |
Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients |
|
- Biological: four doses of Euvax B vaccine
- Biological: 20 μg (1 ml) three doses of Euvax B vaccine
|
Interventional |
Not Applicable |
- Tehran University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Hepatitis B surface antibody mIU/ml
|
51 |
All |
25 Years to 70 Years (Adult, Senior) |
NCT01468051 |
507 |
|
October 2008 |
October 2008 |
October 2008 |
November 9, 2011 |
November 9, 2011 |
|
|
| 31 |
NCT00557219 |
Terminated |
Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery |
|
- Drug: fenoldopam (Corlopam)
- Drug: placebo
- Drug: ketanserin (Sufrexal)
|
Interventional |
Phase 3 |
- Medical University of Gdansk
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- cystatin C and NGAL in serum
- β2microglobulin in urine
- creatinine increase in serum
- frequency of renal replacement therapy
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00557219 |
AMG-NKEBN/225/2007 |
|
April 2008 |
April 2015 |
April 2015 |
November 12, 2007 |
November 15, 2016 |
|
- Department of Cardiac Anesthesiology, Medical University of Gdańsk
Gdańsk, Poland
|
| 32 |
NCT01907061 |
Completed |
Acute Renal Failure Post Liver Transplantation |
|
- Drug: N-acetylcysteine
- Drug: Placebo
|
Interventional |
Not Applicable |
- Baylor Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine levels of pro-inflammatory cytokines and oxidative stress markers in liver transplant patients during post-transplant period
- To correlate changes in pro-inflammatory cytokines and markers of oxidative stress to acute renal failure and acute rejection
- iTo determine the impact of using N-acetylcysteine on cytokines and markers of oxidative stress and the incidence of acute renal failure post liver transplantation
|
30 |
All |
18 Years to 71 Years (Adult, Senior) |
NCT01907061 |
007-157 |
|
July 2007 |
July 2014 |
July 2014 |
July 24, 2013 |
January 13, 2016 |
|
- Annette C. and Harold C. Simmons Tranplant Institute at Baylor Medical Center Dallas
Dallas, Texas, United States
|
| 33 |
NCT01347775 |
Unknown † |
Inspiratory Muscle Training in Patients With End Stage Renal Failure |
- Renal Failure
- Chronic Renal Insufficiency
|
- Device: Inspiratory muscle training (URES HS730)
- Device: Sham inspiratory muscle training (URES HS730)
|
Interventional |
Phase 4 |
- The University of Queensland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Maximal inspiratory pressure (MIP)
- Frenchay activities index
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT01347775 |
IMTRF-06001 |
|
December 2007 |
December 2011 |
February 2012 |
May 4, 2011 |
May 4, 2011 |
|
- Royal Brisbane & Womens Hospital
Brisbane, Queensland, Australia
|
| 34 |
NCT01008631 |
Completed |
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers |
|
|
Interventional |
Not Applicable |
- University Hospital Inselspital, Berne
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Elimination half life in dependence of the degree of renal failure
- Changes in acid-base parameter after application of sodium thiosulfate
|
19 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01008631 |
Uehlinger-002 |
|
September 2009 |
August 2010 |
August 2010 |
November 6, 2009 |
October 13, 2011 |
|
- Department of Nephrology and Hypertension, University of Berne
Berne, Switzerland
|
| 35 |
NCT00304148 |
Active, not recruiting |
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency |
- Renal Insufficiency, Chronic
|
|
Observational |
|
- University of Pennsylvania
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Johns Hopkins University
- (and 5 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The slope of GFR is the primary outcome; Primary outcomes regarding CVD will focus on clinical events indicative of ischemic heart disease, CHF, stroke, and peripheral vascular disease supplemented by radiographic evidence of progressive CVD
- 1.Onset of ESRD; 2.Significant loss of renal function; 3.Composite clinical outcome defined by the occurrence of either 50% decline, or 25 l/min/1.73 m2 decline in GFR from baseline, or onset of ESRD; 4. Slope of change in proteinuria over time.
|
5112 |
All |
45 Years to 79 Years (Adult, Senior) |
NCT00304148 |
DK60990
U01DK060990 |
CRIC |
July 2003 |
June 2018 |
June 2018 |
March 17, 2006 |
February 12, 2018 |
|
- Kaiser Permanente of Northern California
Oakland, California, United States - University of California
San Francisco, California, United States - University of Illinois at Chicago
Chicago, Illinois, United States - (and 10 more...)
|
| 36 |
NCT01170078 |
Completed |
A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment |
|
- Drug: Epoetin Hospira
- Drug: Epogen
|
Interventional |
Phase 1 |
- Hospira, now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Baseline-adjusted area under the serum epoetin concentration curve from the time of dose administration to 48 hours (AUC0-48)
- Maximum serum epoetin concentration (Cmax)
- AUC from time of dose administration to the time of the last measurable concentration (AUC0-t)
- (and 5 more...)
|
107 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01170078 |
EPOE-10-08 |
|
July 2010 |
January 2011 |
January 2011 |
July 27, 2010 |
March 20, 2017 |
|
- Downey, California, United States
- Tarzana, California, United States
- Denver, Colorado, United States
- (and 17 more...)
|
| 37 |
NCT01152411 |
Unknown † |
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Chronic Renal Failure |
|
- Other: Autologous bone marrow stem cells
|
Interventional |
Phase 1
Phase 2 |
- International Stemcell Services Limited
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Significant clinical improvement in serum creatinine and urine output (improvement in measured GFR by 50%)
- Number of patients reporting adverse effects as a measure of safety and tolerability
- Improvement in renal biopsy
|
5 |
All |
18 Years to 65 Years (Adult) |
NCT01152411 |
ISSL-AuBM-CRF |
|
February 2010 |
November 2012 |
November 2012 |
June 29, 2010 |
March 29, 2012 |
|
- St. Theresa's Hospital
Bengaluru, Karnataka, India
|
| 38 |
NCT00684034 |
Completed |
Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality |
- Chronic Renal Insufficiency
|
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- This study should allow to clarify the redox state some plasma by quantification of thiols membranous on the surface of lymphocytes at the hemodialysis and insufficient renal chronic not dialysed patients.
- This study should allow to estimate in a forward-looking longitudinal plan the possible involvement of the parameters of the redox state and the morbidity and the cardiovascular and global mortality in 2 years in 2 studied populations.
|
131 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00684034 |
2007-A01179-44
2007-38 |
|
June 2008 |
April 2012 |
April 2012 |
May 26, 2008 |
August 28, 2014 |
|
- Hopital de la Conception- Service de Néphrologie et de transplantation rénale
Marseille, France
|
| 39 |
NCT00256100 |
Terminated |
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure. |
|
- Drug: Fondaparinux Sodium
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin.
- To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting.
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT00256100 |
2004.066 |
|
June 2004 |
December 2007 |
December 2007 |
November 21, 2005 |
April 12, 2017 |
|
- The Royal Melbourne Hospital Intensive Care Unit Grattan Street
Parkville, Victoria, Australia
|
| 40 |
NCT00532688 |
Unknown † |
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure |
- Heart Failure, Congestive
- Kidney Failure, Chronic
|
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Vascular function via non invasive ultrasound measured flow mediated dilatation
- Estimated glomerular filtration rate calculated with Cockroft Gault equation.
- Symptoms of heart failure
- (and 2 more...)
|
10 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00532688 |
132/07 |
|
September 2007 |
|
February 2008 |
September 20, 2007 |
September 20, 2007 |
|
- Alfred Hospital
Melbourne, Victoria, Australia
|
| 41 |
NCT02621112 |
Recruiting |
HBV Vaccine in Renal Failure Patients |
|
- Biological: Intradermal HBVv with imiquimod
- Biological: Intradermal HBVv with aqueous cream
- Biological: Intramuscular HBVv with aqueous cream
|
Interventional |
Phase 2
Phase 3 |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Seroprotection rate to HBV
- Adverse reaction to hepatitis B vaccine
- GMT fold increase of anti-HBs
|
120 |
All |
21 Years and older (Adult, Senior) |
NCT02621112 |
UW 11-209 |
|
January 2016 |
December 2018 |
March 2019 |
December 3, 2015 |
July 28, 2017 |
|
- University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
|
| 42 |
NCT02848508 |
Not yet recruiting |
Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study |
- Renal Insufficiency, Chronic
|
|
Interventional |
Phase 2 |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Monitoring of blood metformin plasma levels with a fixed dose of metformin
- Monitoring of blood metformin erythrocytes levels with a fixed dose of metformin
|
36 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02848508 |
PI2016_843_0009 |
METsuiviIRC |
September 2016 |
February 2017 |
February 2017 |
July 28, 2016 |
July 28, 2016 |
|
|
| 43 |
NCT00062621 |
Completed |
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure |
- Kidney Failure, Chronic
- Multiple Myeloma
|
- Procedure: Combined bone marrow and kidney transplant
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Immune Tolerance Network (ITN)
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Remission status of multiple myeloma
- Renal allograft acceptance and ability to discontinue immunosuppressive therapy
- Graft vs. host disease (GVHD)
- (and 2 more...)
|
5 |
All |
18 Years to 65 Years (Adult) |
NCT00062621 |
DAIT ITN008ST
NKDO1
DAIT NKDO1 |
|
June 2003 |
December 2006 |
December 2006 |
June 12, 2003 |
February 5, 2013 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 44 |
NCT00270426 |
Terminated |
Benazepril for Advanced Chronic Renal Insufficiency |
|
|
Interventional |
Not Applicable |
- Southern Medical University, China
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 70 Years (Adult, Senior) |
NCT00270426 |
SouthernMUC |
|
|
|
|
December 26, 2005 |
May 5, 2006 |
|
|
| 45 |
NCT01359722 |
Unknown † |
N-acetylcysteine to Prevent Renal Failure |
- Kidney Failure, Acute
- Oxidative Stress Induction
|
- Drug: N-acetylcysteine
- Drug: Control
|
Interventional |
Not Applicable |
- Instituto do Coracao
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Decrease in glomerular filtration defined by at least 30% compared to preoperative levels .
- Up 50% of preoperative levels of serum creatinine.
- Death from any cause.
- (and 5 more...)
|
50 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT01359722 |
0992/09 |
|
March 2010 |
December 2011 |
December 2012 |
May 25, 2011 |
May 25, 2011 |
|
- Instituto do Coracao
Sao Paulo, Brazil
|
| 46 |
NCT01418560 |
Recruiting |
Renal Sympathetic Modification in Patients With Chronic Renal Failure |
|
- Procedure: renal sympathetic modification
|
Interventional |
Not Applicable |
- The Second Affiliated Hospital of Chongqing Medical University
- Jiangsu Provincial People's Hospital
- Chongqing Medical University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the incident of uremia and dialysis requirement
- serum creatinine increases into multiples in 1 month follow-up
- effect of urine microalbumin, urine microalbumin/creatinine, serum creatinine, or 24 hrs urine protein value
- incidence of composite cardiovascular events
|
200 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01418560 |
SWAN-RF |
|
August 2011 |
June 2019 |
June 2020 |
August 17, 2011 |
July 17, 2017 |
|
- 2ndChongqingMU
Chongqing, Chongqing, China
|
| 47 |
NCT02955979 |
Recruiting |
Incidence of Acute Renal Failure Associated With Iodinated Contrast Agents in Pediatrics |
- Acute Renal Insufficiency
|
- Other: CT scan with iodinated contrast agents
|
Observational |
|
- Centre Hospitalier Universitaire de Saint Etienne
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Creatinine
- Diuresis
- Readmission
- (and 3 more...)
|
500 |
All |
up to 16 Years (Child) |
NCT02955979 |
1608041
Y6D1846194a
16-532bis |
CANOPY |
December 8, 2016 |
December 2019 |
December 2019 |
November 4, 2016 |
February 16, 2018 |
|
- CHU de Lyon
Lyon, France - Chu Saint-Etienne
Saint Etienne, France
|
| 48 |
NCT03108924 |
Completed |
The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026) |
|
|
Interventional |
Phase 1 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Concentration-time curve up to infinity
- Concentration-time curve up to last measurement
- Maximum concentration
- (and 7 more...)
|
24 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03108924 |
7264-026 |
|
April 14, 2017 |
September 3, 2017 |
September 13, 2017 |
April 11, 2017 |
September 20, 2017 |
|
- Clinical Pharmacology of Miami ( Site 0001)
Hialeah, Florida, United States - Orlando Clinical Research Center ( Site 0002)
Orlando, Florida, United States
|
| 49 |
NCT00207909 |
Completed |
Study of Patients With Acute Renal Failure on CVVH |
|
|
Observational |
|
- Children's Healthcare of Atlanta
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To determine the underlying etiology of the decrease in urine output seen with the institution of CVVH by examining patient's physiologic hormonal responses.
|
39 |
All |
5 Months and older (Child, Adult, Senior) |
NCT00207909 |
04-114
06585 |
|
February 2005 |
March 2010 |
March 2010 |
September 21, 2005 |
June 14, 2016 |
|
- Children's Healthcare of Atlanta at Egleston
Atlanta, Georgia, United States
|
| 50 |
NCT01208818 |
Completed |
Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy |
- Chronic Renal Failure With Uremic Nephropathy
|
- Drug: Cyclophosphamide + Bortezomib + Dexamethasone regimen
- Drug: Bortezomib +Dexamethasone regimen
- Device: HCO group
- Device: conventional high-flux dialyzer
|
Interventional |
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prevalence of renal response (if dialysis not mandatory at baseline: strata 1); Prevalence of patients free of dialysis (if dialysis required at baseline; strata 2)
- Improvement in renal function
- Hematological response
- (and 3 more...)
|
284 |
All |
18 Years and older (Adult, Senior) |
NCT01208818 |
P081226 |
MYRE |
June 2011 |
September 2015 |
December 2017 |
September 24, 2010 |
December 8, 2017 |
|
- Hôpital Saint Louis
Paris, France
|
Create an RSS feed from your search for:
Download the search results for: